Evogene Partners with Queensland University to Develop AI-Driven Cancer Therapeutics for Chemotherapy-Resistant Lung Cancer
核心洞察
Evogene Ltd. (搜索) has announced a collaboration with Queensland University of Technology to develop novel small-molecule inhibitors targeting chemotherapy resistance in non-small cell lung cancer using AI-driven drug design.
The partnership combines Evogene's ChemPass AI™ platform with Dr. Mark Adams' breakthrough research on a novel cellular detoxification pathway that drives cisplatin resistance in lung cancer patients.
Current treatment resistance rates are significant, with 60-70% of patients showing intrinsic resistance to cisplatin and 30-40% failing to respond to targeted therapies upfront.
Evogene Ltd. (搜索) (Nasdaq: EVGN) (TASE: EVGN) has announced a strategic collaboration with Queensland University of Technology (QUT) to accelerate the discovery of novel cancer therapeutics targeting chemotherapy resistance in non-small cell lung cancer (NSCLC). The partnership combines Evogene's artificial intelligence-driven drug design platform with breakthrough research from Dr. Mark Adams' laboratory on previously unrecognized resistance mechanisms.
Addressing Critical Treatment Resistance
Despite significant advancements in cancer treatment, resistance to standard-of-care therapies remains a major clinical challenge. The effectiveness of cornerstone chemotherapy agents like cisplatin is severely limited by high intrinsic resistance rates, observed in 60-70% of treated patients. Additionally, 30-40% of patients receiving targeted therapies fail to respond initially, while similar resistance patterns are seen in immunotherapy treatments, whether used as monotherapy or in combination with chemotherapy.
These resistance patterns highlight an urgent unmet medical need for more effective therapies that can overcome both intrinsic and acquired treatment resistance in aggressive cancers such as NSCLC.
Novel Therapeutic Target Discovery
The collaboration is based on breakthrough findings from Dr. Adams' laboratory that uncovered a novel druggable cellular detoxification pathway driving cisplatin resistance in NSCLC. This previously unrecognized enzymatic pathway represents a new therapeutic target for overcoming chemotherapy resistance in lung cancer patients.
Dr. Mark Adams from Queensland University of Technology stated: "Partnering with Evogene is an exciting opportunity not only from a cell and molecular biology perspective, but also for its translational potential. Leveraging Evogene's AI-driven technology allows us to accelerate a path from research to real world outcomes. By working together, I look forward to seeing our collective innovation one day make a meaningful difference for people living with cancer."
AI-Driven Drug Design Approach
The partnership leverages Evogene's ChemPass AI™ platform, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. The collaboration will focus on three key areas:
- Pinpointing critical mechanisms within cisplatin-induced detoxification processes that can be therapeutically disrupted
- Applying ChemPass AI™ to generate high-quality chemical leads, prioritizing molecules with strong inhibitory potential and favorable drug-like properties
- Iteratively refining compound design using integrated biological insights from Dr. Adams' lab into ChemPass AI™'s generative model for multi-parameter optimization of drug candidates
Strategic Partnership Goals
The collaboration aims to design novel small-molecule inhibitors that effectively block the critical detoxification mechanism identified by Dr. Adams' research team and restore treatment sensitivity in chemotherapy-resistant patients. By targeting this previously unrecognized pathway, the partnership seeks to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer and potentially other cancer types.
Dr. Gabi Tarcic, Evogene's Chief Development Officer, stated: "By combining Dr. Adams' deep biological insight into resistance pathways with our advanced AI-driven drug design capabilities, we hope to offer a new lifeline to patients who currently face limited treatment options. Partnering with Dr. Adams' research team at QUT marks an important step in extending our generative AI technology into oncology, particularly in tackling one of the most persistent challenges in cancer - chemotherapy resistance."
Company Background
Evogene Ltd. (搜索) is a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. The company's ChemPass AI™ platform significantly improves success rates while reducing development time and costs through its advanced generative molecular design capabilities.